Each pack contains:
1 Bottle of NMN 400mg 60 Vegetarian Capsules
24 Grams of b-NMN per bottle!
400mg NMN (Nicotinamide mononucleotide) Per capsule
Take one or two capsules per a day with breakfast. One bottle should last 30 to 60 days.
Validate this COA here -> https://www.intertek.com/business-assurance/certificate-validation/
WHAT IS NMN?
Nicotinamide mononucleotide (NMN) is a key NAD+ intermediate that has been shown to enhance NAD+ biosynthesis and ameliorate various pathologies in mouse disease models like-
–Decrease β-amyloid buildup
-Restores mitochondrial function
-Normalized impaired glucose tolerance
WHAT IS NAD?
Nicotinamide adenine dinucleotide (NAD) is a co-enzyme that consists of adenine and nicotinamide, it is found in all living cells.
It is commonly seen as a biomarker of aging.
NAD exists in two forms: NAD+ and NADH respectively. NADH contains 2 more electrons than NAD+.
Genetic variations in the genes that interact with NAD can influence how we process this essential molecule.
High NAD+ is necessary for healthy metabolism and mitochondria. In addition, low NAD+ can contribute to fatigue and several diseases.\
When our cells break down carbohydrates and fat for energy, the energy is stored by creating ATP and NADH.
The energy stored in the electrons of NADH can then be converted to ATP via a process called “oxidative phosphorylation” or “cellular respiration” in the mitochondria.
In the presence of food abundance or when our bodies break down [metabolize] more carbohydrates and fats, NADH levels increase, while NAD+ levels decrease.
When electrons go through your mitochondrial electron chain, energy is produced. NADH is the most significant carrier of these electrons and it becomes NAD+ when it gives away those electrons. The body gets energy from food via electrons contained in that food.<1>
HUMAN CLINICAL STUDIES OF NMN
Completed and pending publication
- 2016 Keio University Study – UMIN000021309
- 2017 Keio University Study – UMIN000030609 Phase 2, 8 weeks, 30 subjects
- 2017 Hiroshima University Study – UMIN000025739 24 weeks, 20 subjects, 100 & 200mg
- 2017 University of Washington Study – 8 weeks, 50 subjects
- 2017 Sinclair Metrobio study – Phase 1
- 2018 Sinclair Metrobio study – Phase 2
The Phase 1 study by Dr Sinclair has been completed, and they are ready to go forward with the Phase 2 study, so we can conclude there were positive results, and no negative side effects, else they would have to publish those immediately.
*These statements have not been evaluated by the TGA. This product is not intended to diagnose, treat, cure or prevent any disease.